Why a pharma ETF instead of single stocks?

The biggest pharma risk is the patent cliff: when a key patent expires, a single stock can fall hard. An ETF bundles many companies — if one drops out, the others carry. So you spread exactly the risk that hits single stocks hardest.

Pharma ETF Comparison 2026: The Best Healthcare UCITS ETFs

Q: What is the best pharma ETF for European investors?

For broad, cheap exposure to the global healthcare sector the Xtrackers MSCI World Health Care UCITS ETF (ISIN IE00BM67HK77, TER ~0.25%, accumulating) is one of the largest and cheapest. If you want distributions, the iShares MSCI World Health Care Sector Advanced (IE00BJ5JNZ06, ~0.18%, distributing) is an option.

Q: Pharma ETF or broad healthcare ETF?

Most available ETFs track the whole healthcare sector (pharma, biotech, medtech, services) — broader and more robust than pure pharma. An MSCI World Health Care ETF therefore also covers names like Johnson & Johnson and medical technology.

InvestingPro Editorial Rating: 4.5/5 ★

Before I add a healthcare ETF like the ones below, I check the underlying holdings' fair value and balance-sheet health on InvestingPro — across 1,400+ stocks, including the major pharma names inside these funds.

Start InvestingPro with 15% off →

*Affiliate link — no extra cost to you. Research tool, not a broker, not investment advice.

The main healthcare UCITS ETFs compared

ETF	ISIN	Index	TER p.a.	Distribution
Xtrackers MSCI World Health Care 1C	IE00BM67HK77	MSCI World Health Care	~0.25%	accumulating
iShares MSCI World Health Care Sector Advanced (Dist)	IE00BJ5JNZ06	MSCI World HC Advanced Select (ESG screen)	~0.18%	distributing
Xtrackers MSCI Europe Health Care 1C	LU0292103222	MSCI Europe Health Care	~0.17%	accumulating

Verification as of June 2026. TER/share classes can change — check the current KID before buying.

How to pick the right one

World vs. Europe: the MSCI World Health Care ETFs are global and hold the US heavyweights (J&J, Eli Lilly, UnitedHealth & co.). The Europe ETF is narrower.
Cost: all three are cheap (0.17–0.25%). The iShares Advanced is particularly low at ~0.18% for world exposure — with an ESG screen.
Distribution: for income the distributing iShares Advanced; for wealth building the accumulating Xtrackers.
Sector breadth: "Health Care" covers more than pure pharma — biotech, medtech and services too. That makes the ETF more robust against any single drugmaker's patent cliff.

Why an ETF over single stocks: the very risk that hits pharma single stocks hardest — the patent cliff — is what an ETF diversifies away. If one company falls on a patent expiry, the others carry. For most investors that's the calmer pharma solution.

📊 More context: Pharma hub (Dividend Kings, patent cliff) · Defensive investing · Dividend Strategy · Best High-Yield Dividend Stocks 2026

FAQ

What is the best pharma ETF for European investors?

For broad, cheap world exposure the Xtrackers MSCI World Health Care (IE00BM67HK77, ~0.25%, accumulating). For distributions the iShares MSCI World Health Care Advanced (IE00BJ5JNZ06, ~0.18%, distributing).

Why an ETF instead of single stocks?

The biggest pharma risk is the patent cliff. An ETF bundles many companies — if one drops out, the others carry. You spread exactly the risk that hits single stocks hardest.

Pharma ETF or broad healthcare ETF?

Most ETFs track the whole healthcare sector (pharma, biotech, medtech) — broader and more robust than pure pharma. An MSCI World Health Care ETF also covers J&J, for instance.

Marco Bozem

Private Investor & Analyst | Hard Assets, Dividends | MB Capital Strategies Global

Marco compares ETFs and hard-asset stocks for cost, structure and tax efficiency for European investors. All analysis is based on publicly available fund data. Not investment advice.

Conclusion: for the ETF savings plan on the ETFs above, I use Trade Republic -- zero-euro plan fee.

Open a free Trade Republic account →

*Affiliate link -- no extra cost to you.

Not financial advice. The ETFs mentioned are examples, not buy or sell recommendations. Investing carries price risk up to total loss. TER/share-class data without warranty, as of June 2026 — check the current KID.